M.F.
CโโHโโDโClFโNโOโ
Smiles
O=C(NC([2H])([2H])[2H])C1=CC(OC2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2)=CC=N1
Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8ยฐC) for long term storage
IUPAC Name
4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-(methyl-d3)picolinamide
References
Richly, H., et al.: Int. J. Clin. Pharmacol. Ther., 41, 620 (2003), Khire, U.R., et al.: Bioorg. Med. Chem. Lett., 14, 783 (2004), Wilhelm, S.M., et al.: Cancer Res., 64, 7099 (2004), Rini, B.I., et al.: Expert Opin. Pharmacother., 7, 453 (2006),
Application Notes
Labelled Sorafenib, a potent RAF kinase inhibitor. Antineoplastic.
Purity by HPLC
Not less than 90 %
Hazard Compound
Refer MSDS for complete information
Labelled Sorafenib, a potent RAF kinase inhibitor. Antineoplastic.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Sorafenib-d3 usage and description
Sorafenib D3 is a chemical compound that is commonly used as a targeted therapy for cancer treatment. It is a derivative of Sorafenib, which is an FDA-approved drug used to treat kidney, liver, and thyroid cancers. Sorafenib D3 is a deuterated form of Sorafenib, meaning that it contains three deuterium atoms in place of three hydrogen atoms in its chemical structure. This modification results in improved pharmacokinetic properties, which can lead to better efficacy and safety of the drug.
The mechanism of action of Sorafenib D3 involves inhibition of several protein kinases involved in cancer cell proliferation and angiogenesis. It prevents the growth of tumor cells by blocking the activity of a protein called RAF kinase, which is involved in cell signaling pathways that promote cancer cell growth. Additionally, Sorafenib D3 inhibits the activity of vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs), which are involved in the formation of new blood vessels that supply nutrients to cancer cells.
Sorafenib D3 is typically administered orally in the form of tablets or capsules. It is recommended to be taken on an empty stomach, either one hour before or two hours after a meal. The dosage and duration of treatment may vary depending on the type and stage of cancer being treated, as well as the patient's overall health and other medications being taken.
In conclusion, Sorafenib D3 is an effective targeted therapy for cancer treatment, with improved pharmacokinetic properties compared to its parent compound Sorafenib. Its mechanism of action involves inhibition of several protein kinases involved in cancer cell proliferation and angiogenesis. It is typically administered orally, and the dosage and duration of treatment may vary depending on the specific cancer being treated and the patient's individual needs.
